Summit Global Investments Purchases 15,931 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Global Investments lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5,172.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,239 shares of the biopharmaceutical company’s stock after acquiring an additional 15,931 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 0.9% of Summit Global Investments’ portfolio, making the stock its 21st largest position. Summit Global Investments’ holdings in Regeneron Pharmaceuticals were worth $14,262,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $31,000. MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $37,000. Finally, Sutton Wealth Advisors Inc. grew its position in Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold 10,095 shares of company stock valued at $9,664,476 over the last three months. 8.83% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $34.98 on Thursday, reaching $938.46. The stock had a trading volume of 846,626 shares, compared to its average volume of 495,850. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The company has a market cap of $103.01 billion, a P/E ratio of 26.00, a price-to-earnings-growth ratio of 2.55 and a beta of 0.17. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $944.78 and its two-hundred day moving average is $895.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the firm posted $10.96 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on REGN shares. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Finally, Bank of America upped their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.